Results 91 to 100 of about 32,966 (252)

Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia. [PDF]

Ther Adv Psychopharmacol, 2022
Ma CH, Chan HY, Hsieh MH, Liu CC, Liu CM, Hwu HG, Kuo CH, Chen WJ, Hwang TJ.   +8 more
europepmc   +1 more source

Psychiatric History and Postpartum Depression: The Mediating Role of Obstetric Complications

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Psychiatric history is the strongest risk factor for postpartum depression (PPD). Obstetric complications, more prevalent among women with a psychiatric history, are also independent risk factors. However, the mechanisms linking these factors to PPD remain unclear.
Mette‐Marie Zacher Kjeldsen, Katrine Holde, Line Bager, Veerle Bergink, Emely Ek Blæhr, Janne Tidselbak Larsen, Kathrine Bang Madsen, Merete Lund Mægbæk, Liselotte Vogdrup Petersen, Trine Munk‐Olsen   +9 more
wiley   +1 more source

[Effects of lithium, valproic acid, carbamazepine and antipsychotic agents on cognition in bipolar disorders-A systematic review]. [PDF]

Nervenarzt, 2023
Leopold S, Quante A.
europepmc   +1 more source

Clinical Intervention Following Detection of Incident Diabetes Within a Large Psychiatric Service System: A Chart Review Study

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Individuals with mental illness have a markedly reduced life expectancy, partly due to a significantly increased risk of developing type 2 diabetes, driven by lifestyle factors and the adverse metabolic effects of psychotropic medications.
Pernille Kølbæk, Christopher Rohde, Maria Speed, Henrik Holm Thomsen, Søren Dinesen Østergaard   +4 more
wiley   +1 more source

Proportion of High-dose Antipsychotic Therapy and Prescription Pattern in Patients Diagnosed with Schizophrenia from a Tertiary Care Hospital in Nepal: An Observational Study

Journal of Nepal Medical Association
Introduction: High-dose antipsychotic therapy, defined as dosing exceeding 100% of the British National Formulary recommended  maximum daily dose, is associated with increased risk of adverse effects and is generally discouraged by clinical guidelines ...
Lujaw Ratna Tuladhar, Nidhi Rajeshwori Thapa, Jibeshwori Wagle, Suraj Sharma   +3 more
doaj   +1 more source

Electroconvulsive Therapy and Time to Psychiatric Readmission in Schizophrenia

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction There is evidence that electroconvulsive therapy (ECT) can augment the effects of antipsychotics in schizophrenia. However, there is limited evidence from Western populations on whether ECT reduces the risk of relapse compared to non‐ECT treatment in schizophrenia.
Linnea Stenmark, Mussie Msghina, Axel Nordenskjöld   +2 more
wiley   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

Incidental Resolution of Dopamine Agonist Induced Impulse Control Disorder with GLP‐1 Receptor Agonist

Movement Disorders Clinical Practice, EarlyView.
Hannah Kelly, Thomas Davis
wiley   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

A call for action: Closing the evidence gap in management of stimulant‐induced psychosis

Addiction, EarlyView.
Abstract Background Stimulant‐induced psychosis (StIP) is emerging as one of most pressing health challenges. Over the past two decades, stimulant‐related harms and psychiatric care demands have risen sharply. Individuals with StIP often present with severe agitation and high suicide risk, and up to half progress to chronic psychotic illness within two
Anne Bouthillier, Heidar Sharafi, Adam Bisaga, Didier Jutras‐Aswad   +3 more
wiley   +1 more source